Reveal the invisible.
Save lives.

Innovate. Save lives.

Make informed, more efficient clinical decisions

Each and every day, we push the boundaries of innovation with solutions that help save lives.

Why choose Myrian?

Focus on what’s important

Achieve faster interpretation, more precise diagnosis and more efficient follow-up.

Use advanced, fully integrated visualisation tools

Build feature-rich clinical apps and the best artificial intelligence systems directly into your workflow.
Request a demo

Making artificial intelligence invisible

At a time when artificial intelligence is one of the hottest topic in medical imaging, we’re working to make it invisible!

Our technology lets radiologists and clinicians focus on quality of care by building artificial intelligence systems into their workflow, all with a focus on clinical needs.

Our natively AI-powered clinical apps are built to the highest clinical standards.

Innovation & research are hardwired into our DNA

At Intrasense, we’ve been focused on research and innovation since the company's creation, investing more than 25% of our revenues in this field.

Each and every day, our teams work alongside healthcare professionals to develop cutting-edge clinical tools and shape a seamless, secure user experience.

Innovative, collaborative solutions fully integrated into any healthcare information system

1,000 customers
worldwide
Certificates of conformity in
40 countries

20 advanced
clinical apps
170 scientific papers
and several technology patents

Our success stories

The Dimeo Imagerie Médicale group chooses Myrian applications for a collaborative work

Interview with Jean-Philippe NUEFFER, Radiologist:

"Myrian® gives satisfaction to our team on a clinical level, but above all it is an easy-to-use and adaptable tool: its functionalities are customizable and scalable. We benefited from a tailor-made support and were able to customize this tool to our practice."

Interview with Jean-Pierre MAZET, Director of IFMEM Tours

"Myrian® is the ideal solution by definition. It was absolutely fundamental to equip us with a solution that is used extensively at many sites on a routine basis and to have special options for teaching purposes. We are very pleased to keep up, so effectively, with the advances in medicine in terms of technological progress and ensure state-of-the-art training for our students."

Interview with Professor Housset

"Myrian® is a unique solution for optimizing exam reading and increasing the quality of diagnosis and therapeutic discussions; it contributes significantly to improving the quality of patient care and pathology monitoring."

Intrasense news

Intrasense announces the appointment of Jérôme Thiebaud as Chief Business Officer

24 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the appointment of Jérôme Thiebaud as the Group's Chief Business Officer.
Find out more

Liflow®: an innovative AI-enhanced solution to optimize oncology follow-up

16 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the regulatory submission of its Liflow® 1.0 solution (registered trademark of the Myra project), an oncology platform dedicated to the analysis of diagnostic imaging and cancer follow-up.
Find out more

Intrasense and Guerbet announce CE certification of Myrian 2.12, enhanced with Guerbet's prostate AI

8 April 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian®, and Guerbet (FR0000032526 GBT), world leader in medical imaging, are proud to announce that the Myrian® 2.12 platform has obtained CE certification under MDR, integrating prostate AI developed by Guerbet, the Veolity® LungCAD AI developed by MeVis Medical Solutions AG […]
Find out more

2023 annual results

20 March 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and the developer of Myrian® (the "Company"), today announced its annual 2023 IFRS consolidated financial results certified at Group level.
Find out more

Intrasense presents its innovations at the European Congress of Radiology (ECR) 2024

26 February 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, announces its participation at the ECR from February 28 to March 3, in Vienna (Austria).
Find out more

Intrasense announces the certification of Myrian® to the new European regulation (MDR)

21 February 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, is proud to announce that the company has obtained the new CE certification under MDR (European Union Medical Device Regulation 2017/745), authorizing the marketing of the latest version of its Myrian® solution.
Find out more

Intrasense announces annual revenue for 2023

8 February 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian® (the "Company"), today announced its 2023 consolidated IFRS revenue (uncertified) at Group level.
Find out more

Intrasense announces its financial agenda for 2024

31 January 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, announces the dates of its next financial communications for the year 2024.
Find out more

Intrasense announces strategic partnership with EDL, French leader in digital healthcare solutions

18 October 2023
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, has announced the signature of a strategic partnership with EDL. French leader in software packages for technical platforms of public and private healthcare establishments, EDL develops Xplore®, a radiology solution. This partnership will enable the integration and marketing of Myrian® clinical […]
Find out more

2023 Half-year results: sales growth and continued investment policy

20 September 2023
Intrasense (FR0011179886 - ALINS), spécialiste des solutions logicielles d’imagerie médicale et concepteur de Myrian®, annonce ses résultats semestriels 2023 consolidés aux normes IFRS. Etant précisé que suite à l’OPA volontaire du groupe Guerbet, clôturée en date du 5 juin 2023, le groupe Intrasense est maintenant intégré dans le périmètre de consolidation du groupe Guerbet.
Find out more

Intrasense attends the 2023 « Journées Francophones de Radiologie »

13 September 2023
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, announces its attendance in the 2023 “Journées Francophones de la Radiologie” (JFR), where new innovative solutions incorporating artificial intelligence will be presented.
Find out more

Intrasense signs a strategic contract with Ebit to market its solutions in Italy

11 July 2023
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, and Ebit, part of the italian group Esaote, specialized in the development of software solutions for diagnostic imaging, announce their strategic partnership to market Intrasense solutions in Italy.
Find out more

Intrasense and Guerbet sign a licensing and integration agreement for artificial intelligence in oncology medical imaging

19 June 2023
Intrasense (FR0011179886 - ALINS), spécialiste des solutions logicielles d’imagerie médicale et concepteur de Myrian®, et Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announce the signature on June 19, 2023 of a license agreement to integrate and market Guerbet's artificial intelligence algorithms within Intrasense software platforms.
Find out more

Intrasense announces the co-option of a new director and the appointment of a new Chairman of its Board of Directors

25 May 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, annonces, the co-option of a new director to the Board, also appointed Chairman of the Board.
Find out more

2022 annual results: continued investments and renewed growth ambition

30 March 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and designer of Myrian® (the "Company"), today announced its consolidated (unaudited) 2022 IFRS financial results at Group level.
Find out more

Intrasense strengthens its porfolio with the signature of a contract with SATT Sud-Est

27 March 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, announces the signature of a technology transfer contract with SATT Sud-Est that will allow the company to acquire artificial intelligence algorithms dedicated to the detection of pulmonary nodules in radiology. These algorithms were developed by the Medical Imaging Unit of the Assistance Publique-Hôpitaux de […]
Find out more

Intrasense and the ICM sign a partnership to optimize a new solution dedicated to oncology

6 February 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, has joined forces with the Montpellier Cancer Institute (ICM) through a partnership aimed at validating and then deploying its new platform dedicated to oncology in real-life situations, with the objective of using it in clinical routine.
Find out more

Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions

11 January 2023
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions ("Intrasense" or the "Company") announces that the Guerbet Group (FR0000032526 - GBT) has acquired a 39% stake in its share capital through a reserved share capital increase for a total amount of 8.8 million euros at an issuance price of 0.44 euro per share, […]
Find out more

Presentation of the half-yearly financial results 2022

21 October 2022
On the occasion of the publication of the half-yearly results 2022, Intrasense will give an update on its latest developments.
Find out more

2022-half-year results: continued growth momentum

12 October 2022
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® (the "Group"), today announces its 2022 IFRS Group consolidated half-year financial results.
Find out more
1 2 3 6

Your questions answered

How does Myrian integrate into ris and pacs systems? How do i deploy Myrian?
Myrian can be launched from the worklist in a RIS or PACS system, with smart, direct access to the right display protocol for the type of exam that needs to be interpreted. Myrian integrates fully into your work environment, irrespective of how it’s deployed. Of course, there’s a deployment method to suit every organisation, since it’s available in standalone, application server and web-access format.
Can i customise Myrian to suit my user preferences?
You can customise the display modes yourself, according to your preferences. Our team can also help you customise your keyboard, mouse and layout shortcuts.
What support will i get once it’s installed?
Our sales team will provide personal support and answer questions you may have over time. You’ll get access to training and an on-site or remote follow-up service, day and night. Our Support engineers, based in Montpellier, are available on the phone or by email from Monday to Friday for day-to-day remote support.*
* Support disponible via l’année de garantie ou la souscription de notre contrat de service 
Contact support
How do i access future myrian versions and updates? How often are these released?
If you’ve signed up for a service contract, you’ll get all the latest features of Myrian when each new version is released, depending on the apps you have installed. You can also request a demo of new clinical modules. A maintenance release is available each month, and two major version releases each year.
chevron-down